Suchergebnisse - "NY22HMQ4BX"

PubPharm (890)

1

Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer : Results from the open-label, multicentre, non-interventional BRAWO study

enthalten in: International journal of cancer | 2024

von Lüftner, D. | Schuetz, F. | Schneeweiss, A. | +14

2

Towards clinical adherence monitoring of oral endocrine breast cancer therapies by LC-HRMS-method development, validation, comparison of four sample matrices, and proof of concept

enthalten in: Analytical and bioanalytical chemistry | 2024

von Jacobs, C. | Radosa, J. | Wagmann, L. | +8

3

Exemestane plus everolimus and palbociclib in metastatic breast cancer : clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial

enthalten in: Nature communications | 2024

von Gómez Tejeda Zañudo, J. | Barroso-Sousa, R. | Jain, E. | +15

4

The effect of exemestane administration on the lipid profile in women : Meta-analysis of randomized controlled trials

enthalten in: European journal of obstetrics, gynecology, and reproductive biology | 2024

von Yang, L. | Xiang, Y. | Wu, S. | +3

5

p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane

enthalten in: British journal of cancer | 2024

von Vanacker, H. | Treilleux, I. | Schiffler, C. | +16

6

Resveratrol-Exemestane Beneficial Regimen to Overcome the Complications over Existing Therapies for the Management of Breast Cancer

enthalten in: Current molecular medicine | 2024

von Kaur, S. | Singh, D.

7

Phase II study of apatinib plus exemestane in estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer

enthalten in: Cancer biology & therapy | 2023

von Tan, A. | Nong, L. | Wang, H. | +7

8

Effect of variables on exemestane-loaded albumin nanoparticles : statistical optimization and anti-cancer activity in MCF-7 cell lines

enthalten in: Pharmaceutical development and technology | 2023

von Vyas, D. | Wairkar, S.

9

Incorporation of exemestane into ternary nanosponge system for enhanced anti-tumor potential in breast cancer

enthalten in: Pharmaceutical development and technology | 2023

von Mane, P. | Wakure, B. | Wakte, P.

10

Acute generalized exanthematous pustulosis induced by exemestane during adjuvant radiotherapy for breast cancer

enthalten in: Medicina clinica | 2023

von Ferini, G. | Zagardo, V. | Strazzanti, A.

CommentOn: Med Clin (Barc). 2021 Sep 10;157(5):260-261. - PMID 32843220

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[89]